Home
#Global Trends
#Local Dynamics
#M&A
#Regulations
#Knowledge

Category: Uncategorized

Viatris Exits Preferred Equity Stake in Biocon Biologics in Major Transaction

09/12/2025 Published by vivi

The global healthcare enterprise Viatris has executed definitive agreements for the divestiture of its entire convertible preferred equity holding in... Read more

Tags: #M&A

Sandoz Finalizes Acquisition of Just-Evotec Biologics EU SAS, Reinforcing Biosimilars Leadership

08/12/2025 Published by vivi

(Basel, December 8, 2025) – Sandoz Group AG (SIX: SDZ/OTCQX: SDZNY), the global leader in affordable medicines, announced the successful... Read more

Category: Uncategorized

Tags: #M&A

AstraZeneca’s Dual-Targeting CAR-T Shows Encouraging Efficacy

08/12/2025 Published by vivi

(ASH Congress) – AstraZeneca (AZ) announced positive clinical data for its leading cell therapy candidate, AZD0120 (formerly GC012F), for the... Read more

Category: Uncategorized

Tags: #Global Trends

Crescent and Kelun-Biotech Execute Double Deal to Swap Cancer Asset Rights

08/12/2025 Published by vivi

The pharmaceutical companies Crescent Biopharma (US-based) and Kelun-Biotech (China-based) have announced a strategic partnership to exchange licensing rights for two... Read more

Category: Uncategorized

Tags: #Global Trends

Trial Data Opens Door for Earlier Use of Lilly’s BTK Inhibitor

08/12/2025 Published by vivi

(ORLANDO) – At an American Society of Hematology (ASH) meeting, the pharmaceutical company Eli Lillypresented results from a critical head-to-head... Read more

Category: Uncategorized

Tags: #Global Trends

Pharma Megamerger: Major Drug Company Unifies $5.5 Billion Biologics Subsidiary

07/12/2025 Published by vivi

A major pharmaceutical company has announced the successful completion of a plan to fully integrate its Biologics subsidiary, officially making... Read more

Category: Uncategorized

Tags: #M&A

AstraZeneca Expands Amyloidosis Collaboration with Deal Potentially Reaching $780 Million

07/12/2025 Published by vivi

Alexion Pharmaceuticals, the rare disease unit of AstraZeneca, has expanded its partnership with biotech company Neurimmune by licensing a second... Read more

Category: Uncategorized

Tags: #Global Trends

Major Funding Deal: Therapeutics Company Secures $275 Million Through Drug Royalty Agreement

07/12/2025 Published by vivi

A therapeutics company has announced a funding agreement worth $275 million with a financial fund specializing in pharmaceutical royalties. The... Read more

Category: Uncategorized

Tags: #Global Trends